50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
One Stock Doubles Your Money, During Crisis? (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
One Stock Doubles Your Money, During Crisis? (Ad)
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
How to profit from the coming boom in gold (Ad)
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
One Stock Doubles Your Money, During Crisis? (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
One Stock Doubles Your Money, During Crisis? (Ad)
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
How to profit from the coming boom in gold (Ad)
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
One Stock Doubles Your Money, During Crisis? (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
One Stock Doubles Your Money, During Crisis? (Ad)
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
How to profit from the coming boom in gold (Ad)
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
One Stock Doubles Your Money, During Crisis? (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
One Stock Doubles Your Money, During Crisis? (Ad)
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
How to profit from the coming boom in gold (Ad)
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
NASDAQ:ATXI

Avenue Therapeutics - ATXI Price Target & Analyst Ratings

$3.52
-0.98 (-21.78%)
(As of 09/26/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.48
$4.38
50-Day Range
$3.21
$67.50
52-Week Range
$3.00
$27.75
Volume
494,344 shs
Average Volume
204,453 shs
Market Capitalization
$77.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Avenue Therapeutics Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

N/A
Based on 0 Analyst Ratings

Consensus Analyst Price Target

N/A

TypeCurrent
9/27/21 to 9/27/22
1 Month Ago
8/28/21 to 8/28/22
3 Months Ago
6/29/21 to 6/29/22
1 Year Ago
9/27/20 to 9/27/21
Consensus RatingN/AN/AN/A
Hold
Strong Buy N/A N/A N/A
0 Strong Buy rating(s)
Buy N/A N/A N/A
0 Buy rating(s)
Hold N/A N/A N/A
1 Hold rating(s)
Sell N/A N/A N/A
0 Sell rating(s)
Consensus Price TargetN/AN/AN/A$90.00
Predicted UpsideN/AN/AN/A10.09% Upside
Get Avenue Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.


ATXI Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ATXI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Avenue Therapeutics Stock vs. The Competition

TypeAvenue TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
0.00
2.68
2.49
Consensus RatingN/ABuyHold
Predicted Upside1,121.67% Upside34.59% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
145
59.92%
Underperform Votes
97
40.08%
Avg. Outperform Votes
165
66.53%
Avg. Underperform Votes
83
33.47%
Avg. Outperform Votes
852
68.38%
Avg. Underperform Votes
394
31.62%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/18/2020HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Arce
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold$90.00+10.09%
(Data available from 9/27/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ATXI Price Target - Frequently Asked Questions

Do MarketBeat users like Avenue Therapeutics more than its competitors?

MarketBeat users like Avenue Therapeutics less than other Medical companies. 59.92% of MarketBeat users gave Avenue Therapeutics an outperform vote while medical companies recieve an average of 66.67% outperform votes by MarketBeat users.


Stock Ratings Reports and Tools

This page (NASDAQ:ATXI) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.